We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+10.47%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$850M
AUM Growth
-$111M
Cap. Flow
-$61.2M
Cap. Flow %
-7.2%
Top 10 Hldgs %
87.63%
Holding
26
New
2
Increased
1
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$74.6M
2
UPB
Upstream Bio Inc
UPB
+$51.3M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$5.21M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$117M
2
IRON icon
Disc Medicine
IRON
+$47M
3
ANNX icon
Annexon
ANNX
+$19.7M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$8.32M
5
NAUT icon
Nautilus Biotechnolgy
NAUT
+$576K

Sector Composition

Rank Sector Weight
1 Healthcare 99.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.34B
$275M 32.41%
10,719,110
+245,197
+2% +$5.21M
NUVL
2
DELISTED
Nuvalent
NUVL
$113M 13.33%
1,447,267
-1,250,000
-46% -$117M
PHVS icon
3
Pharvaris
PHVS
$2.44B
$63.3M 7.45%
3,303,381
– –
IRON icon
4
Disc Medicine
IRON
$2.97B
$62.4M 7.33%
983,500
-812,235
-45% -$47M
DNTH icon
5
Dianthus Therapeutics
DNTH
$6.09B
$58.6M 6.9%
2,689,707
-323,716
-11% -$8.32M
SVRA icon
6
Savara
SVRA
$1.19B
$44.7M 5.26%
14,565,457
– –
OLMA icon
7
Olema Pharmaceuticals
OLMA
$1.05B
$43.6M 5.12%
+7,470,214
New +$74.6M
UPB
8
Upstream Bio Inc
UPB
$395M
$37.7M 4.44%
+2,295,322
New +$51.3M
ANNX icon
9
Annexon
ANNX
$886M
$26.9M 3.17%
5,249,069
-3,200,679
-38% -$19.7M
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$18.9M 2.22%
703,080
– –
SLDB icon
11
Solid Biosciences
SLDB
$900M
$16.1M 1.9%
4,034,582
– –
KYTX icon
12
Kyverna Therapeutics
KYTX
$484M
$12.6M 1.48%
3,368,370
– –
XFOR icon
13
X4 Pharmaceuticals
XFOR
$460M
$12.4M 1.46%
563,859
– –
MRSN
14
DELISTED
Mersana Therapeutics
MRSN
$12.4M 1.46%
346,547
– –
TNGX icon
15
Tango Therapeutics
TNGX
$4.41B
$8.38M 0.99%
2,712,008
– –
AVIR icon
16
Atea Pharmaceuticals
AVIR
$420M
$8.33M 0.98%
2,485,638
– –
RPID icon
17
Rapid Micro Biosystems
RPID
$86.2M
$7.59M 0.89%
8,434,560
– –
CABA icon
18
Cabaletta Bio
CABA
$455M
$6.27M 0.74%
2,760,888
– –
IPSC icon
19
Century Therapeutics
IPSC
$361M
$5.46M 0.64%
5,410,361
– –
XLO icon
20
Xilio Therapeutics
XLO
$60.3M
$4.36M 0.51%
326,201
– –
CCCC icon
21
C4 Therapeutics
CCCC
$412M
$4M 0.47%
1,111,910
– –
NAUT icon
22
Nautilus Biotechnolgy
NAUT
$115M
$2.96M 0.35%
1,759,000
-241,000
-12% -$576K
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.44M 0.17%
2,693,380
– –
NAMSW icon
24
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$1.43M 0.17%
100,000
– –
IVVD icon
25
Invivyd
IVVD
$218M
$797K 0.09%
1,799,595
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2024 Portfolio in Review

As of Q4 2024, Bain Capital Life Sciences Investors held 26 positions worth $850M, down 12% from $961M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $61.2M in Q4 2024, reducing 5 holdings. Its largest reduction was Nuvalent, cutting an estimated $117M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Olema Pharmaceuticals worth $43.6M.

  • Bain Capital Life Sciences Investors's largest Q4 2024 buy was Olema Pharmaceuticals: 7,470,214 shares worth $43.6M.
  • Bain Capital Life Sciences Investors added most to NewAmsterdam Pharma in Q4 2024, an estimated $5.21M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $117M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 88% of its $850M portfolio in Q4 2024.
  • Bain Capital Life Sciences Investors opened 2 new positions and closed 0 in Q4 2024.
  • Bain Capital Life Sciences Investors's portfolio value fell 12% quarter-over-quarter to $850M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2024, filed 14 Feb 2025.